Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2021
This report can be delivered to the clients within 3-4 working days
DelveInsight’s, “Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Cyclin-dependent-kinase-inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cyclin-dependent-kinase-inhibitors: Overview
Cyclin-dependent kinases (CDKs) are a family of enzymes-serine threonine kinases - that, under normal physiological conditions, play significant roles in controlling cell-cycle progression and transcription regulation. Overexpression of some CDKs and their associated cyclins, as well as downregulation of CDK inhibitors (CKIs), can lead to abnormal cellular proliferation and cancer progression. Due to such dysregulation of CDKs in many cancers, targeting of this family of enzymes has emerged as a promising strategy in the treatment of multiple cancer types, including blood and solid tumours. Targeting the cell cycle via the CDK4/6-Rb axis has proven the most successful approach in the clinic to date. The FDA has approved the CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib as treatments for hormone receptor-positive (HR+) metastatic breast cancer (mBC), in combination with endocrine therapy.
'Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cyclin-dependent-kinase-inhibitors pipeline landscape is provided which includes the disease overview and Cyclin-dependent-kinase-inhibitors treatment guidelines. The assessment part of the report embraces, in depth Cyclin-dependent-kinase-inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cyclin-dependent-kinase-inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cyclin-dependent-kinase-inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclin-dependent-kinase-inhibitors Emerging Drugs
Further product details are provided in the report.
Cyclin-dependent-kinase-inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Cyclin-dependent-kinase-inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Cyclin-dependent-kinase-inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cyclin-dependent-kinase-inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-dependent-kinase-inhibitors drugs.
Cyclin-dependent-kinase-inhibitors Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Cyclin-dependent-kinase-inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cyclin-dependent-kinase-inhibitors: Overview
Cyclin-dependent kinases (CDKs) are a family of enzymes-serine threonine kinases - that, under normal physiological conditions, play significant roles in controlling cell-cycle progression and transcription regulation. Overexpression of some CDKs and their associated cyclins, as well as downregulation of CDK inhibitors (CKIs), can lead to abnormal cellular proliferation and cancer progression. Due to such dysregulation of CDKs in many cancers, targeting of this family of enzymes has emerged as a promising strategy in the treatment of multiple cancer types, including blood and solid tumours. Targeting the cell cycle via the CDK4/6-Rb axis has proven the most successful approach in the clinic to date. The FDA has approved the CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib as treatments for hormone receptor-positive (HR+) metastatic breast cancer (mBC), in combination with endocrine therapy.
'Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cyclin-dependent-kinase-inhibitors pipeline landscape is provided which includes the disease overview and Cyclin-dependent-kinase-inhibitors treatment guidelines. The assessment part of the report embraces, in depth Cyclin-dependent-kinase-inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cyclin-dependent-kinase-inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cyclin-dependent-kinase-inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Cyclin-dependent-kinase-inhibitors.
This segment of the Cyclin-dependent-kinase-inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclin-dependent-kinase-inhibitors Emerging Drugs
- SHR6390: Jiangsu Hengrui Medicine Co.
- GB491 (lerociclib): Genor Pharma
Further product details are provided in the report.
Cyclin-dependent-kinase-inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Cyclin-dependent-kinase-inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cyclin-dependent-kinase-inhibitors
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Cyclin-dependent-kinase-inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cyclin-dependent-kinase-inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-dependent-kinase-inhibitors drugs.
Cyclin-dependent-kinase-inhibitors Report Insights
- Cyclin-dependent-kinase-inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cyclin-dependent-kinase-inhibitors drugs?
- How many Cyclin-dependent-kinase-inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cyclin-dependent-kinase-inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cyclin-dependent-kinase-inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cyclin-dependent-kinase-inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Syros Pharmaceuticals
- Jiangsu Hengrui Medicine
- Aucentra Therapeutics
- Nuvation Bio
- MEI Pharma
- Vincerx Pharma
- Chordia Therapeutics
- Genor Pharma
- SY-5609
- SHR-6390
- Auceliciclib
- AU2-94
- AU14-5
- AU2-85
- AU4-53
- NUV-422
- Voruciclib
- VIP-152
- CRD-1835439
- GB491
Introduction
Executive Summary
Cyclin-dependent-kinase-inhibitors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
GB491: Genor Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early stage products (Phase I)
Comparative Analysis
Voruciclib: MEI Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical stage products
Comparative Analysis
AU2-94: Aucentra Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Cyclin-dependent-kinase-inhibitors Key Companies
Cyclin-dependent-kinase-inhibitors Key Products
Cyclin-dependent-kinase-inhibitors- Unmet Needs
Cyclin-dependent-kinase-inhibitors- Market Drivers and Barriers
Appendix
Executive Summary
Cyclin-dependent-kinase-inhibitors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
GB491: Genor Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early stage products (Phase I)
Comparative Analysis
Voruciclib: MEI Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical stage products
Comparative Analysis
AU2-94: Aucentra Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Cyclin-dependent-kinase-inhibitors Key Companies
Cyclin-dependent-kinase-inhibitors Key Products
Cyclin-dependent-kinase-inhibitors- Unmet Needs
Cyclin-dependent-kinase-inhibitors- Market Drivers and Barriers
Appendix
LIST OF TABLES
Table 1 Total Products for Cyclin-dependent-kinase-inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cyclin-dependent-kinase-inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cyclin-dependent-kinase-inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cyclin-dependent-kinase-inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
